Publications

Export 29 results:
Sort by: Author Title Type [ Year  (Desc)]
unknown year
, , (unknown year) Abstract
n/a
, , (unknown year) Abstract
n/a
, , (unknown year) Abstract
n/a
, , (unknown year) Abstract
n/a
, , (unknown year) Abstract
n/a
, , (unknown year) Abstract

n/a

, , (unknown year) Abstract

n/a

, , (unknown year) Abstract

n/a

, , (unknown year) Abstract

n/a

, , (unknown year) Abstract

n/a

Impact of relatively new chemotherapeutic agents on the outcome of Egyptian patients with advanced malignant pleural mesothelioma, Gaafar, R., Khaled H., Sallam YA, Shafik H., Aboulkassem FA, and Emara M. , Forum of Clinical Oncology, Volume 5, Issue 1, p.29-36, (unknown year) Abstract
n/a
Prognostic Significance of Progenitor Cell Markers CD34/CD38 Expression in Acute Myeloid Leukemia (AML) Egyptian Patients, Mostafa, Naglaa, Rashed Reham A., Mohamed Waleed S., and Shafik Hanan E. , (unknown year) Abstract
n/a
2019
Frequency of germline mutations in BRCA1 and BRCA2 in ovarian cancer patients and their effect on treatment outcome., Ashour, Mohamed, and Shafik Hanan Ezzat , Cancer management and research, Volume 11, p.6275-6284, (2019) Abstract

Aim of work: Reporting the incidence and the variants of /2 mutations in ovarian cancer patients exploring their effects on the treatment outcomes.

Patients and methods: In total, 104 patients with epithelial ovarian cancer were prospectively recruited to the study. Analysis consisted of the sequencing of all the translated exons and immediately adjacent intronic regions of the genes. Responses to multiple lines of chemotherapy were assessed, as well as the effect of gene mutations on progression-free survival (PFS) and overall survival (OS).

Results: Pathogenic / mutations were found in 21.15% of the patients. mutations represented 68.2% of the total mutations. Two novel mutations were identified. Age at diagnosis was a strong predictor of the presence of a pathogenic mutation. Patients with a family history of cancer had a higher incidence of mutations (=0.005). As high as 72% of the patients with BRCA mutations were diagnosed at advanced stage. High-grade serous tumors have a higher incidence of pathogenic mutation (=0.07). Response to neoadjuvant chemotherapy was high (93.9%). All patients underwent surgery which was optimal in 73.1% of the patients. As high as 85.6% of the patients received adjuvant chemotherapy. Relapse rate was 45.2%. Visceral metastasis was more often in BRCA carriers (=0.01). Patients carrying pathogenic BRCA1/2 mutations had a longer median PFS of 42.43 months (95% CI 32.04-52.83) compared to 22.24 months (95% CI 14.83-29.58) for non-carriers (=0.08). OS was 64.32 months (95% CI 38.09-90.06) for BRCA mutation patients versus 56.63 months (95% CI 50.05-63.21) (=0.04) for non-carriers. In multivariate analysis, early stage at diagnosis and optimal debulking were the only independent predictors of better PFS and OS.

Conclusion: We documented a number of pathogenic and mutations in this patients cohort; two novel mutations were detected. BRCA status seemed to affect survival in ovarian cancer patients.

2018
Associations of interleukin-10 gene polymorphisms with acute myeloid leukemia in human (Egypt), Rashed, Reham, Shafik Roxan E., Shafik Nevine F., and Shafik Hanan E. , (2018) Abstract
n/a
2017
Association of CYP3A5* 3 and CYP1A1* 2C polymorphism with development of acute myeloid leukemia in Egyptian patients, WAHAB, NAHED ABDEL, Shafik Nevine F., Shafik Roxan E., Taha Sherin A., Shafik Hanan E., and Darwish Amira D. , Asian Pacific journal of cancer prevention: APJCP, Volume 18, Issue 3, p.747, (2017) Abstract
n/a
The Meningioma 1 (MN1) Gene is an Independent Poor Prognostic Factor in Adult Egyptian Acute Myeloid Leukemia Patients, Shafik, Roxan E., Hassan Naglaa M., Elmeligui Yomna M., and Shafik Hanan E. , Asian Pacific journal of cancer prevention: APJCP, Volume 18, Issue 3, p.609, (2017) Abstract
n/a
Prognosis and Outcome of Adult Patients with Ewing Sarcoma (Local Experience), Ashour, Mohamed, Al Shammari Salem, SHAFIK HANAN, and Mohialdien Ahmed , Journal of Cancer Therapy, Volume 8, Issue 08, p.764, (2017) Abstract
n/a
2016
Retrospective Analysis of Adjuvant Therapy in Intermediate and High Risk Endometrial Cancer Patients, Shafik, Hanan E., Alshemmary Salem H., and Ashour Mohamed , Journal of Cancer Therapy, Volume 7, Issue 07, p.545, (2016) Abstract
n/a
2015
Frequency of EGFR Mutation and EML4-ALK fusion gene in Arab Patients with Adenocarcinoma of the Lung, Shafik, Hanan Ezzat, and Ashour Mohamed , Forum of Clinical Oncology, Volume 6, Issue 2, p.19-23, (2015) Abstract
n/a
Prognostic significance of plasma osteopontin level in breast cancer patients, Nassar, Hanan R., Namour Alfred E., Shafik Hanan E., El Sayed Amr S., Kamel Samar M., Moneer Manar M., and Zakhary Nadia I. , Forum of Clinical Oncology, Volume 6, Issue 1, p.27-32, (2015) Abstract
n/a
Prognostic value of a CYP2B6 gene polymorphism in patients with acute myeloid leukemia, Alazhary, Nevin M., Shafik Roxan E., Shafik Hanan E., and Kamel Mahmoud M. , Asian Pacific Journal of Cancer Prevention, Volume 16, Issue 11, p.4583-4587, (2015) Abstract
n/a
2014
Frequency of Epidermal Growth Factor Mutation Status and Its Effect on Outcome of Patients with Adenocarcinoma of the Lung, Shafik, Hanan E., Al-Shemarri Salem H., Al-Enezi Fahed, Ashour Mohamed, Khalaf Eman, and Al-Khodary Ahmed I. , Journal of Cancer Therapy, Volume 5, Issue 11, p.1012, (2014) Abstract
n/a
Gemcitabine and cisplatin as neoadjuvant chemotherapy for invasive transitional and squamous cell carcinoma of the bladder: effect on survival and bladder preservation, Khaled, Hussein M., Shafik Hanan E., Zabhloul MS, Ghoneim M., Saber RA, Manie M., Enein HA, Megeed HA, Mansur O., and Sherbini ME , Clinical genitourinary cancer, Volume 12, Issue 5, p.e233-e240, (2014) Abstract
n/a
Impact of New Chemotherapeutic agents on the out-come of Egyptian patients with Advanced Malignant Pleural Mesothelioma, Gaafar, R., Sallam YA, Shafik HE, Aboulkassem FA, Emara M., and Khaled H. , The Gulf journal of oncology, Volume 1, Issue 16, p.56-63, (2014) Abstract
n/a
2013
Impact of PIVKA-II in diagnosis of hepatocellular carcinoma, Zakhary, Nadia I., Khodeer Sherif M., Shafik Hanan E., and Malak Camelia Abdel A. , Journal of advanced research, Volume 4, Issue 6, p.539-546, (2013) Abstract
n/a
2012
The palliative prognostic index for the prediction of survival and in-hospital mortality of patients with advanced cancer in Kuwait, Alshemmari, Salem, Ezzat Hanan, Samir Zainab, Samar Refaat, and Alsirafy Samy A. , Journal of palliative medicine, Volume 15, Issue 2, p.200-204, (2012) Abstract
n/a
2010
Symptom burden in hospitalized patients with cancer in Kuwait and the need for palliative care, Alshemmari, Salem, Ezzat Hanan, Samir Zainab, Sajnani Kamlesh, and Alsirafy Samy , American Journal of Hospice and Palliative Medicine®, Volume 27, Issue 7, p.446-449, (2010) Abstract
n/a
2009
CA 125, a new prognostic marker for aggressive NHL, EL GAWAD, IMAN ABD A., and Shafik Hanan E. , J Egypt Natl Canc Inst, Volume 21, Issue 3, p.209-17, (2009) Abstract
n/a